

Marcela Ferres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10742258/publications.pdf>

Version: 2024-02-01

42
papers

1,387
citations

361413

20
h-index

345221

36
g-index

44
all docs

44
docs citations

44
times ranked

1814
citing authors

#	ARTICLE	IF	CITATIONS
1	High prevalence of SARS-CoV-2 detection and prolonged viral shedding in stools: A Systematic Review and Cohort Study. <i>GastroenterologÃa Y HepatologÃa</i> , 2022, , .	0.5	7
2	Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile. <i>Nature Microbiology</i> , 2022, 7, 524-529.	13.3	22
3	Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile. <i>Science Advances</i> , 2021, 7, .	10.3	29
4	Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003415.	8.4	72
5	A simple RNA preparation method for SARS-CoV-2 detection by RT-qPCR. <i>Scientific Reports</i> , 2020, 10, 16608.	3.3	60
6	Mother-to-Child Transmission of Andes Virus through Breast Milk, Chile. <i>Emerging Infectious Diseases</i> , 2020, 26, 1885-1888.	4.3	13
7	Characterization of Oral Immunity in Cases and Close Household Contacts Exposed to Andes Orthohantavirus (ANDV). <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 557273.	3.9	1
8	Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia. <i>Journal of Clinical Virology</i> , 2020, 132, 104657.	3.1	9
9	Comparison of VSV Pseudovirus and Focus Reduction Neutralization Assays for Measurement of Anti-Andes orthohantavirus Neutralizing Antibodies in Patient Samples. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 444.	3.9	3
10	Symptom Profiles and Risk Factors for Hospitalization in Patients With SARS-CoV-2 and COVID-19: A Large Cohort From South America. <i>Gastroenterology</i> , 2020, 159, 1148-1150.	1.3	26
11	Platelet Count in Patients with Mild Disease at Admission is Associated with Progression to Severe Hantavirus Cardiopulmonary Syndrome. <i>Viruses</i> , 2019, 11, 693.	3.3	11
12	Deletions in Genes Participating in Innate Immune Response Modify the Clinical Course of Andes Orthohantavirus Infection. <i>Viruses</i> , 2019, 11, 680.	3.3	12
13	A 19 Year Analysis of Small Mammals Associated with Human Hantavirus Cases in Chile. <i>Viruses</i> , 2019, 11, 848.	3.3	6
14	A Single-Nucleotide Polymorphism of $\beta 23$ Integrin Is Associated with the Andes Virus Infection Susceptibility. <i>Viruses</i> , 2019, 11, 169.	3.3	6
15	Evaluation of monoclonal antibodies that detect conserved proteins from Respiratory Syncytial Virus, Metapneumovirus and Adenovirus in human samples. <i>Journal of Virological Methods</i> , 2018, 254, 51-64.	2.1	12
16	Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. <i>Nature Immunology</i> , 2017, 18, 464-473.	14.5	131
17	Serum levels of interleukin-6 are linked to the severity of the disease caused by Andes Virus. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005757.	3.0	35
18	Zika Virus Infection in a Non-Mosquito-Borne Transmission Country. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0

#	ARTICLE	IF	CITATIONS
19	Molecular method for the detection of Andes hantavirus infection: validation for clinical diagnostics. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 36-39.	1.8	20
20	Hantavirus cardiopulmonary syndrome successfully treated with high-volume hemofiltration. <i>Revista Brasileira De Terapia Intensiva</i> , 2016, 28, 190-4.	0.3	6
21	Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF- α , With Severity of Disease Caused by Andes Virus. <i>Clinical Infectious Diseases</i> , 2015, 61, e62-e69.	5.8	17
22	Rapid Enzyme-Linked Immunosorbent Assay for the Detection of Hantavirus-Specific Antibodies in Divergent Small Mammals. <i>Viruses</i> , 2014, 6, 2028-2037.	3.3	6
23	Person-to-Person Household and Nosocomial Transmission of Andes Hantavirus, Southern Chile, 2011. <i>Emerging Infectious Diseases</i> , 2014, 20, 1637-1644.	4.3	92
24	Hantaviruses and cardiopulmonary syndrome in South America. <i>Virus Research</i> , 2014, 187, 43-54.	2.2	95
25	Respiratory syncytial virus detection in cells and clinical samples by using three new monoclonal antibodies. <i>Journal of Medical Virology</i> , 2014, 86, 1256-1266.	5.0	12
26	A rapid method for infectivity titration of Andes hantavirus using flow cytometry. <i>Journal of Virological Methods</i> , 2013, 193, 291-294.	2.1	17
27	High-Dose Intravenous Methylprednisolone for Hantavirus Cardiopulmonary Syndrome in Chile: A Double-Blind, Randomized Controlled Clinical Trial. <i>Clinical Infectious Diseases</i> , 2013, 57, 943-951.	5.8	59
28	Rates of Hospital-Acquired Influenza Due to the Pandemic H1N1 Virus in 2009, Compared with Seasonal Influenza. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 198-200.	1.8	5
29	Infection of human monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory state, the secretion of active MMP-9 and indirectly enhances endothelial permeability. <i>Virology Journal</i> , 2011, 8, 223.	3.4	42
30	Andes virus infections in the rodent reservoir and in humans vary across contrasting landscapes in Chile. <i>Infection, Genetics and Evolution</i> , 2010, 10, 819-824.	2.3	13
31	Highly Differentiated, Resting Gn-Specific Memory CD8+ T Cells Persist Years after Infection by Andes Hantavirus. <i>PLoS Pathogens</i> , 2010, 6, e1000779.	4.7	43
32	Range expansion of <i>Oligoryzomys longicaudatus</i> (Rodentia, Sigmodontinae) in Patagonian Chile, and first record of Hantavirus in the region. <i>Revista Chilena De Historia Natural</i> , 2009, 82, .	1.2	25
33	Andes Virus Antigens Are Shed in Urine of Patients with Acute Hantavirus Cardiopulmonary Syndrome. <i>Journal of Virology</i> , 2009, 83, 5046-5055.	3.4	37
34	Ecology, Genetic Diversity, and Phylogeographic Structure of Andes Virus in Humans and Rodents in Chile. <i>Journal of Virology</i> , 2009, 83, 2446-2459.	3.4	60
35	Prospective Evaluation of Household Contacts of Persons with Hantavirus Cardiopulmonary Syndrome in Chile. <i>Journal of Infectious Diseases</i> , 2007, 195, 1563-1571.	4.0	128
36	Neutralizing Antibodies in Survivors of Sin Nombre and Andes Hantavirus Infection. <i>Emerging Infectious Diseases</i> , 2006, 12, 166-168.	4.3	47

#	ARTICLE	IF	CITATIONS
37	Incubation Period of Hantavirus Cardiopulmonary Syndrome. <i>Emerging Infectious Diseases</i> , 2006, 12, 1271-1273.	4.3	64
38	Hantavirus infection in children. <i>Current Opinion in Pediatrics</i> , 2004, 16, 70-75.	2.0	32
39	PREVALENCE OF ANTIBODIES TO HANTAVIRUS AMONG FAMILY AND HEALTH CARE WORKER CONTACTS OF PERSONS WITH HANTAVIRUS CARDIOPULMONARY SYNDROME: LACK OF EVIDENCE FOR NOSOCOMIAL TRANSMISSION OF ANDES VIRUS TO HEALTH CARE WORKERS IN CHILE. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 70, 302-304.	1.4	21
40	PERIDOMESTIC SMALL MAMMALS ASSOCIATED WITH CONFIRMED CASES OF HUMAN HANTAVIRUS DISEASE IN SOUTHCENTRAL CHILE. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 70, 305-309.	1.4	53
41	Prevalence of antibodies to hantavirus among family and health care worker contacts of persons with hantavirus cardiopulmonary syndrome: lack of evidence for nosocomial transmission of Andes virus to health care workers in Chile. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 70, 302-4.	1.4	5
42	Peridomestic small mammals associated with confirmed cases of human hantavirus disease in southcentral Chile. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 70, 305-9.	1.4	28